Morgan Stanley lowered the firm’s price target on BioMarin (BMRN) to $96 from $97 and keeps an Overweight rating on the shares. The firm notes in an earnings preview that for Q2 its estimates are in line with the Street on revenues, but further out its sees BioMarin having under-appreciated revenue potential.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical: Undervalued Stock with Promising Growth Catalysts and Positive Outlook
- BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment
- BioMarin price target raised to $113 from $108 at JPMorgan
- BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment
- BioMarin assumed with an Overweight at Morgan Stanley